李攀;钱家鸣;

• 1:中国医学科学院北京协和医学院北京协和医院消化内科

摘要(Abstract)：

<正>炎症性肠病(inflammatory bowel disease,IBD)是以反复发作的慢性肠道炎症为特点的一组疾病,主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn disease,CD),同时伴有多种肠道外表现。骨质疏松症是一种以骨量低下、骨微结构破坏、骨脆性增加、易发生骨折为特征的全身性骨病,同时也是IBD严重却

关键词(KeyWords)： 炎症性肠病;骨质疏松

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李攀;钱家鸣;

Email:

DOI:

参考文献(References)：

• [1]Genant HK,Mall JC,Wagonfeld JB,et al.Skeletal demi-neralization and growth retardation in inflammatory bowel dis-ease[J].Invest Radiol,1976,11:541-549.
• [2]Noble CL,McCullough J,Ho W,et al.Lowbody mass not vitamin D receptor polymorphisms predict osteoporosis in pa-tients with inflammatory bowel disease[J].Aliment Phar-macol Ther,2008,27:588-596.
• [3]Pollak RD,Karmeli F,Eliakim R,et al.Femoral neck os-teopenia in patients with inflammatory bowel disease[J].Am J Gastroenterol,1998,93:1483-1490.
• [4]Bjarnason I,Macpherson A,Mackintosh C,et al.Reduced bone density in patients with inflammatory bowel disease[J].Gut,1997,40:228-233.
• [5]Card T,WestJ,Hubbard R,etal.Hip fractures in patients with inflammatory bowel disease and their relationship to cor-ticosteroid use:a population based cohort study[J].Gut,2004,53:251-255.
• [6]Van Staa TP,Leufkens HG,and CooperC.The epidemiolo-gy of corticosteroid-induced osteoporosis:a meta-analysis[J].Osteoporos Int,2002,13:777-787.
• [7]Bernstein CN,Leslie WD.The pathophysiology of bone dis-ease in gastrointestinal disease[J].Eur J Gastroenterol Hepatol,2003,15:857-864.
• [8]Manolagas SC.The role of IL-6type cytokines and their re-ceptors in bone[J].Ann N Y Acad Sci,1998,840:194-204.
• [9]Schulte CM,Dignass AU,Goebell H,et al.Genetic factors determine extent of bone loss in inflammatory bowel disease[J].Gastroenterology,2000,119:909-920.
• [10]Boyce BF,Xing L.The RANKL/RANK/OPG pathway[J].Curr Osteoporos Rep,2007,5:98-104.
• [11]Bernstein CN,Sargent M,and Leslie WD.Serum osteopro-tegerin is increased in Crohn s disease:a population-based case control study[J].Inflamm Bowel Dis,2005,11:325-330.
• [12]Moschen AR,Kaser A,Enrich B,et al.The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss[J].Gut,2005,54:479-487.
• [13]Hofbauer LC,Lacey DL,Dunstan CR,et al.Interleukin-1beta and tumor necrosis factor-alpha,but not interleukin-6,stimulate osteoprotegerin ligand gene expression in human osteoblastic cells[J].Bone,1999,25:255-259.
• [14]Miheller P,Muzes G,Racz K,et al.Changes of OPG and RANKL concentrations in Crohn s disease after infliximab therapy[J].Inflamm Bowel Dis,2007,13:1379-1384.
• [15]Gong Y,Slee RB,Fukai N,et al.LDL receptor-related protein5(LRP5)affects bone accrual and eye development[J].Cell,2001,107:513-523.
• [16]Mizuguchi T,Furuta I,Watanabe Y,et al.LRP5,low-density-lipoprotein-receptor-related protein5,is a determi-nant for bone mineral density[J].J Hum Genet,2004,49:80-86.
• [17]TodhunterCE,Sutherland-Craggs A,BartramSA,etal.In-fluence of IL-6,COL1A1,and VDR gene polymorphisms on bone mineral density in Crohn s disease[J].Gut,2005,54:1579-1584.
• [18]Asomaning K,Bertone-Johnson ER,Nasca PC,et al.The association between body mass index and osteoporosis in pa-tients referred fora bone mineral density examination[J].J Womens Health(Larchmt),2006,15:1028-1034.
• [19]刘建彬,高翔,张芳宾,等.炎症性肠病并发低骨量/骨质疏松的危险因素分析[J].中华内科杂志,2009,48:833-836.
• [20]张文燕,袁耀宗.炎症性肠病患者骨代谢状况评估[J].中华消化杂志,2009,29:437-441.
• [21]Silvennoinen J,Lamberg-Allardt C,Karkkainen M,et al.Dietary calciumintake and its relation to bone mineral densi-ty in patients with inflammatory bowel disease[J].J Intern Med,1996,240:285-292.
• [22]Gilman J,Shanahan F,and Cashman KD.Determinants of vitamin D status in adultCrohn s disease patients,with parti-cular emphasis on supplemental vitamin D use[J].Eur J Clin Nutr,2006,60:889-896.
• [23]Cashman KD,Shanahan F.Is nutrition an aetiological factor for inflammatory bowel disease?[J].Eur J Gastroenterol Hepatol,2003,15:607-613.
• [24]罗林枝,徐苓.维生素K与骨质疏松[J].中国医学科学院学报,2003,25:346-349.
• [25]Duggan P,O Brien M,Kiely M,et al.Vitamin K status in patients with Crohn s disease and relationship to bone turn-over[J].Am J Gastroenterol,2004,99:2178-2185.
• [26]Bernstein CN,Leslie WD,Leboff MS.AGA technical re-viewon osteoporosis in gastrointestinal diseases[J].Gas-troenterology,2003,124:795-841.
• [27]Scott EM,Gaywood I,Scott BB.Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease.British Society of Gastroenterology[J].Gut,2000,46Suppl1:i1-8.
• [28]Palomba S,Manguso F,Orio F Jr,et al.Effectiveness of risedronate in osteoporotic postmenopausal women with in-flammatory bowel disease:a prospective,parallel,open-la-bel,two-year extension study[J].Menopause,2008,15(4Pt1):730-736.
• [29]Chesnut CH3rd,Silverman S,Andriano K,et al.A ran-domized trial of nasal spray salmon calcitonin in postmenopa-usal women with established osteoporosis:the prevent recur-rence of osteoporotic fractures study.PROOF Study Group[J].Am J Med,2000,109:267-276.
• [30]Vestergaard P,Rejnmark L,Mosekilde L.Fracture risk as-sociated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures[J].Calcif Tissue Int,2008,82:249-257.
• [31]Schoon EJ,Bollani S,Mills PR,et al.Bone mineral densi-ty in relation to efficacy and side effects of budesonide and prednisolone in Crohn s disease[J].Clin Gastroenterol Hepatol,2005,3:113-121.
• [32]Reffitt DM,Meenan J,Sanderson JD,et al.Bone density improves with disease remission in patients with inflammatory bowel disease[J].EurJ Gastroenterol Hepatol,2003,15:1267-1273.
• [33]Franchimont N,Putzeys V,Collette J,et al.Rapid im-provement of bone metabolism after infliximab treatment in Crohn s disease[J].Aliment Pharmacol Ther,2004,20:607-614.
• [34]Abreu MT,Geller JL,Vasiliauskas EA,et al.Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn s disease[J].J Clin Gas-troenterol,2006,40:55-63.
• [35]Ryan BM,Russel MG,Schurgers L,et al.Effect of antitu-mour necrosis factor-alpha therapy on bone turnover in pa-tients with active Crohn s disease:a prospective study[J].Aliment Pharmacol Ther,2004,20:851-857.
• [36]Pazianas M,Rhim AD,Weinberg AM,et al.The effect of anti-TNF-alpha therapy on spinal bone mineral density in pa-tients with Crohn s disease[J].Ann NY Acad Sci,2006,1068:543-556.